- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04314401
Narodowy Instytut Raka „Biobank Cancer Moonshot”
Protokół badań biobanku raka Moonshot
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
Przegląd badań
Status
Warunki
- Złośliwy nowotwór lity
- Czerniak
- Ostra białaczka szpikowa
- Szpiczak mnogi
- Anatomiczny rak piersi III stopnia AJCC v8
- Anatomiczny rak piersi IV stadium AJCC v8
- Rak jajowodu
- Rak żołądka
- Rak niedrobnokomórkowy płuc
- Rak płuc w stadium III AJCC v8
- Rak płuc w stadium IV AJCC v8
- Przerzutowy rak prostaty
- Rak jajnika
- Rak przełyku
- Inwazyjny rak piersi
- Rak prostaty w stadium IVB AJCC v8
- Rak żołądka w stadium IV AJCC v8
- Stopień kliniczny IV gruczolakorak połączenia żołądkowo-przełykowego AJCC v8
- Potrójnie ujemny rak piersi
- Rak jelita grubego w stadium IV AJCC v8
- Pierwotny rak otrzewnej
- Stopień kliniczny IV gruczolakoraka przełyku AJCC v8
- Rak surowiczy wysokiego stopnia jajnika
- Rak jajowodu stopnia III AJCC v8
- Rak jajnika stopnia III AJCC v8
- Rak jajowodu w stadium IV AJCC v8
- Rak jajnika w stadium IV AJCC v8
- Rak piersi z dodatnim receptorem hormonalnym
- Rak drobnokomórkowy płuc
Szczegółowy opis
PRIMARY OBJECTIVE:
I. To support current and future investigations into drug resistance and sensitivity and other National Cancer Institute (NCI)-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment at NCI Community Oncology Research Program (NCORP) sites and other National Clinical Trials Network (NCTN) sites.
SECONDARY OBJECTIVES:
I. To provide a service of value to study participants and their medical providers through the performance of molecular profiling assays on tumor samples in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory and reporting of results to physicians and patients that they may opt to use in clinical management, including analysis of data for acquired resistance mechanisms.
II. To enable the development of patient-derived models such as cell lines and xenografts for cancer researchers through the provision of biospecimens from up to 20% of study participants to the NCI's Patient Derived Models Repository (PDMR), a national resource available to investigators.
III. To develop and implement robust approaches in patient and provider engagement to improve understanding of biobanking and its relationship to cancer research and increase representation of minority and underserved study participants in cancer research.
IV. To develop increased capabilities in United States (U.S.) community hospitals and clinics for contribution to cancer research through biobanking activities.
V. To enable secondary research generated from the project through deposition of data in public repositories such as Cancer Research Data Commons (CRDC), The Cancer Imaging Archive (TCIA) and database of Genotypes and Phenotypes (dbGaP) and other potential NCI databases, including clinical, radiology and pathology data with an emphasis on treatment response and outcome data.
VI. To provide residual biospecimens and associated data from the project to the cancer research community.
OUTLINE:
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo computed tomography (CT), positron emission tomography (PET)/CT and/or magnetic resonance imaging (MRI) throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
San Juan, Portoryko, 00917
- San Juan Community Oncology Group
-
San Juan, Portoryko, 00927
- Centro Comprensivo de Cancer de UPR
-
San Juan, Portoryko, 00936
- San Juan City Hospital
-
-
-
-
Alabama
-
Daphne, Alabama, Stany Zjednoczone, 36526
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope, Alabama, Stany Zjednoczone, 36532
- Thomas Hospital
-
Mobile, Alabama, Stany Zjednoczone, 36607
- Mobile Infirmary Medical Center
-
Saraland, Alabama, Stany Zjednoczone, 36571
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Kingman, Arizona, Stany Zjednoczone, 86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Fort Smith, Arkansas, Stany Zjednoczone, 72903
- Mercy Hospital Fort Smith
-
-
California
-
Arroyo Grande, California, Stany Zjednoczone, 93420
- PCR Oncology
-
Bakersfield, California, Stany Zjednoczone, 93301
- AIS Cancer Center at San Joaquin Community Hospital
-
Loma Linda, California, Stany Zjednoczone, 92357
- Veterans Affairs Loma Linda Healthcare System
-
Salinas, California, Stany Zjednoczone, 93901
- Salinas Valley Memorial
-
-
Colorado
-
Brighton, Colorado, Stany Zjednoczone, 80601
- Intermountain Health Platte Valley Hospital
-
Denver, Colorado, Stany Zjednoczone, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Golden, Colorado, Stany Zjednoczone, 80401
- Lutheran Hospital - Cancer Centers of Colorado
-
Grand Junction, Colorado, Stany Zjednoczone, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Lafayette, Colorado, Stany Zjednoczone, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
-
Connecticut
-
Hartford, Connecticut, Stany Zjednoczone, 06102
- Hartford Hospital
-
-
Delaware
-
Dover, Delaware, Stany Zjednoczone, 19901
- Bayhealth Hospital Kent Campus
-
Milford, Delaware, Stany Zjednoczone, 19963
- Bayhealth Hospital Sussex Campus
-
-
Florida
-
Boca Raton, Florida, Stany Zjednoczone, 33486
- Boca Raton Regional Hospital
-
Deerfield Beach, Florida, Stany Zjednoczone, 33064
- Broward Health North
-
Fort Lauderdale, Florida, Stany Zjednoczone, 33316
- Broward Health Medical Center
-
Tampa, Florida, Stany Zjednoczone, 33606
- Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30342
- Northside Hospital
-
Savannah, Georgia, Stany Zjednoczone, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Illinois
-
Bloomington, Illinois, Stany Zjednoczone, 61704
- Illinois CancerCare-Bloomington
-
Chicago, Illinois, Stany Zjednoczone, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Stany Zjednoczone, 60625
- Swedish Covenant Hospital
-
Danville, Illinois, Stany Zjednoczone, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Evanston, Illinois, Stany Zjednoczone, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Stany Zjednoczone, 61401
- Illinois CancerCare-Galesburg
-
Glenview, Illinois, Stany Zjednoczone, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Stany Zjednoczone, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Mattoon, Illinois, Stany Zjednoczone, 61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon, Illinois, Stany Zjednoczone, 62864
- SSM Health Good Samaritan
-
Pekin, Illinois, Stany Zjednoczone, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Stany Zjednoczone, 61615
- Illinois CancerCare-Peoria
-
Urbana, Illinois, Stany Zjednoczone, 61801
- Carle Cancer Center
-
Washington, Illinois, Stany Zjednoczone, 61571
- Illinois CancerCare - Washington
-
-
Iowa
-
Ames, Iowa, Stany Zjednoczone, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Stany Zjednoczone, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Cedar Rapids, Iowa, Stany Zjednoczone, 52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids, Iowa, Stany Zjednoczone, 52402
- Physicians' Clinic of Iowa PC
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- Blank Children's Hospital
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Iowa City, Iowa, Stany Zjednoczone, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Stany Zjednoczone, 70808
- Our Lady of the Lake Physician Group
-
New Orleans, Louisiana, Stany Zjednoczone, 70118
- Children's Hospital New Orleans
-
New Orleans, Louisiana, Stany Zjednoczone, 70112
- University Medical Center New Orleans
-
Shreveport, Louisiana, Stany Zjednoczone, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Augusta, Maine, Stany Zjednoczone, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, Stany Zjednoczone, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Stany Zjednoczone, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brunswick, Maine, Stany Zjednoczone, 04011
- MaineHealth Cancer Care and IV Therapy - Brunswick
-
Brunswick, Maine, Stany Zjednoczone, 04011
- Mid Coast Hospital
-
Damariscotta, Maine, Stany Zjednoczone, 04543
- MaineHealth LincolnHealth Hospital
-
Farmington, Maine, Stany Zjednoczone, 04938
- MaineHealth Franklin Hospital
-
Lewiston, Maine, Stany Zjednoczone, 04240
- Saint Mary's Regional Medical Center
-
Norway, Maine, Stany Zjednoczone, 04268
- MaineHealth Stephens Hospital
-
Portland, Maine, Stany Zjednoczone, 04102
- Maine Medical Partners Surgical Care
-
Portland, Maine, Stany Zjednoczone, 04102
- MMP Surgical Care Casco Bay
-
Portland, Maine, Stany Zjednoczone, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Stany Zjednoczone, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Stany Zjednoczone, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Stany Zjednoczone, 04074
- Maine Children's Cancer Program
-
Scarborough, Maine, Stany Zjednoczone, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Stany Zjednoczone, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
South Portland, Maine, Stany Zjednoczone, 04106
- MaineHealth Urology - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Stany Zjednoczone, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Stany Zjednoczone, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Stany Zjednoczone, 48118
- Chelsea Hospital
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Iron Mountain, Michigan, Stany Zjednoczone, 49801
- Dickinson County Healthcare System
-
Livonia, Michigan, Stany Zjednoczone, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Stany Zjednoczone, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
-
Missouri
-
Ballwin, Missouri, Stany Zjednoczone, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Joplin, Missouri, Stany Zjednoczone, 64804
- Freeman Health System
-
Joplin, Missouri, Stany Zjednoczone, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Stany Zjednoczone, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Stany Zjednoczone, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Stany Zjednoczone, 64506
- Heartland Regional Medical Center
-
Springfield, Missouri, Stany Zjednoczone, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Stany Zjednoczone, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Stany Zjednoczone, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Stany Zjednoczone, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Stany Zjednoczone, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Stany Zjednoczone, 63128
- Mercy Hospital South
-
Washington, Missouri, Stany Zjednoczone, 63090
- Mercy Hospital Washington
-
-
Montana
-
Billings, Montana, Stany Zjednoczone, 59102
- Saint Vincent Frontier Cancer Center
-
Butte, Montana, Stany Zjednoczone, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
-
Nebraska
-
Grand Island, Nebraska, Stany Zjednoczone, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
-
Nevada
-
Carson City, Nevada, Stany Zjednoczone, 89703
- Carson Tahoe Regional Medical Center
-
Las Vegas, Nevada, Stany Zjednoczone, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Stany Zjednoczone, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Stany Zjednoczone, 89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Stany Zjednoczone, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Stany Zjednoczone, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Hampshire
-
Nashua, New Hampshire, Stany Zjednoczone, 03060
- Saint Joseph Hospital
-
-
New Jersey
-
Morristown, New Jersey, Stany Zjednoczone, 07960
- Morristown Medical Center
-
Newton, New Jersey, Stany Zjednoczone, 07860
- Newton Medical Center
-
Pompton, New Jersey, Stany Zjednoczone, 07444
- Chilton Medical Center
-
Summit, New Jersey, Stany Zjednoczone, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, Stany Zjednoczone, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
The Bronx, New York, Stany Zjednoczone, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Stany Zjednoczone, 10467
- Children's Hospital at Montefiore
-
The Bronx, New York, Stany Zjednoczone, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Stany Zjednoczone, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, Stany Zjednoczone, 27834
- East Carolina University
-
Greenville, North Carolina, Stany Zjednoczone, 27834
- ECU Health Medical Center
-
Kernersville, North Carolina, Stany Zjednoczone, 27284
- Novant Health Cancer Institute - Kernersville
-
Kinston, North Carolina, Stany Zjednoczone, 28501
- ECU Health Oncology Kinston
-
Mount Airy, North Carolina, Stany Zjednoczone, 27030
- Novant Health Cancer Institute - Mount Airy
-
Pinehurst, North Carolina, Stany Zjednoczone, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Thomasville, North Carolina, Stany Zjednoczone, 27360
- Novant Health Cancer Institute - Thomasville
-
Washington, North Carolina, Stany Zjednoczone, 27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27103
- Novant Health Forsyth Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73120
- Mercy Hospital Oklahoma City
-
-
Rhode Island
-
Providence, Rhode Island, Stany Zjednoczone, 02908
- Roger Williams Medical Center
-
-
South Carolina
-
Columbia, South Carolina, Stany Zjednoczone, 29203
- Prisma Health Richland Hospital
-
Columbia, South Carolina, Stany Zjednoczone, 29220
- Prisma Health Baptist Hospital
-
Gaffney, South Carolina, Stany Zjednoczone, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, Stany Zjednoczone, 29605
- Prisma Health Greenville Memorial Hospital
-
Greer, South Carolina, Stany Zjednoczone, 29651
- Gibbs Cancer Center-Pelham
-
Spartanburg, South Carolina, Stany Zjednoczone, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Stany Zjednoczone, 29379
- SMC Center for Hematology Oncology Union
-
-
Texas
-
San Antonio, Texas, Stany Zjednoczone, 78229
- Audie L Murphy VA Hospital
-
-
Virginia
-
Lynchburg, Virginia, Stany Zjednoczone, 24501
- Centra Alan B Pearson Regional Cancer Center
-
Richmond, Virginia, Stany Zjednoczone, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stany Zjednoczone, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Renton, Washington, Stany Zjednoczone, 98055
- Valley Medical Center
-
Yakima, Washington, Stany Zjednoczone, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Huntington, West Virginia, Stany Zjednoczone, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Stany Zjednoczone, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Eau Claire, Wisconsin, Stany Zjednoczone, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Stany Zjednoczone, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53215
- Aurora Saint Luke's Medical Center
-
Minocqua, Wisconsin, Stany Zjednoczone, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Stany Zjednoczone, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Stany Zjednoczone, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Stany Zjednoczone, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Stany Zjednoczone, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Patients undergoing treatment for cancer types with commercially available therapies.
Opis
Inclusion Criteria:
-
Is consistent with OR has been diagnosed with one of the following:
-
Colorectal cancer: stage IV
-
Non-small cell or small cell lung cancer: stage III/IV
-
Prostate cancer: metastatic prostate cancer
-
Gastric cancer, not otherwise specified (NOS): stage IV
-
Esophageal cancer, NOS: stage IV
-
Adenocarcinoma of gastroesophageal junction: stage IV
-
High grade serous ovarian cancer: stage III/IV
-
Invasive breast carcinoma: stage III/IV
-
Melanoma: stage III/IV
-
Acute myeloid leukemia
-
Multiple myeloma
-
For the purposes of this study,
- Re-staging is allowed
- Having more than one primary cancer is allowed, if the patient is being treated solely for one of the eligible cancers listed above
-
-
-
Patient should fit in one of the following four clinical scenarios (a-d)
- Undergoing diagnostic workup for one of the diseases listed for which treatment will likely include a new regimen of standard of care therapy OR
- Scheduled to begin treatment with a new regimen of standard of care therapy OR
- Currently progressing on a regimen of standard of care therapy OR
- Currently being treated with a regimen standard of care therapy, without evidence of progression
-
Requirements for fresh tissue biospecimen collections at enrollment:
-
For clinical scenarios a, b, and c above, freshly collected tumor tissue or bone marrow (BM) aspirate must be submitted at enrollment
-
For clinical scenarios a and b, the fresh tissue collection must be prior to starting therapy
-
For clinical scenario a, the biospecimen collection must be part of a standard of care medical procedure
-
For clinical scenarios b or c, the biospecimen collection may be part of a standard of care medical procedure OR
-
The biospecimen collection may be part of a study-specific procedure ("research only biopsy"), when the patient has a tumor amenable to image guided or direct vision biopsy and is willing and able to undergo a tumor biopsy for molecular profiling
- Note: For research-only biopsies, the biopsy must not be associated with a significant risk of severe or major complications or death; the procedure cannot be a mediastinal, laparoscopic, open or endoscopic biopsy; nor can the procedure be a brain biopsy; nor can the patient be under the age of majority as determined by each U.S. state
-
-
-
Requirements for archival tissue:
-
For clinical scenarios a and b above, archival tissue as outlined below must be submitted IF AVAILABLE
-
For clinical scenarios c and d above, archival tissue as outlined below is REQUIRED
-
Pre-existing archival material (formalin-fixed, paraffin-embedded [FFPE] block, BM aspirate, or unstained slides) that:
- Contains the cancer type for which the participant is enrolled, and
- Was collected no more than 5 years prior to initiation of therapy, and
- Contains at least a surface area of 5 mm^2 and optimal surface area of 25 mm^2 or 3-5 mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, and
- Contains at least 10% tumor content. 70% tumor content is optimal, and
- No more than 1 line of standard of care systemic therapy was administered from the date of archival material collection to the date of initiation of therapy
-
-
Requirements for blood collection: ALL scenarios require fresh blood collection at enrollment
- Blood collection for clinical scenarios a, b, and c must take place within 1 week of fresh tumor specimen collection
- Blood collection for clinical scenario d must take place within 4 weeks of enrollment, and while patient is on treatment
-
Age 13 or older
-
Any sex
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
-
Ability to understand and willingness to sign an informed consent document. Consent may be provided by a Legally Authorized Representative (LAR) in accordance with 45 CFR 46.102(i)
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC who are 40 years old or younger at time of collection irrespective of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with BRCA that are either
- Any race/ethnicity with hormone receptor positive (ER+PR+, ER+PR-, or ER-PR+)
- African American with triple negative (ER-PR-HER2-)
-
NCI PDMR INCLUSION CRITERIA: Patients with lung cancer (LCA), prostate cancer (PCA), gastroesophageal cancer (GEC), ovarian cancer (OV), acute myeloid leukemia (AML), multiple myeloma (MML)
Exclusion Criteria:
-
Treated with or has already begun treatment with a non-standard of care therapeutic agent (investigational) in an interventional clinical trial
- For the purposes of this study, past enrollment in clinical trials whereby the patient was randomized and treated with standard-of-care anti-cancer treatment (chemotherapy regimen, surgery and radiation therapy) is allowed
-
Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy
-
Use of full dose coumarin-derivative anticoagulants such as warfarin are prohibited. Patients may be switched to low molecular weight (LMW) heparin at physician discretion
-
Low molecular weight (LMW) heparin is permitted for prophylactic or therapeutic use
-
Factor X inhibitors are permitted
-
Use of anti-platelet drugs are permitted
- Stopping the anticoagulation treatment for biopsy, bone marrow aspirate, or resection should be per site standard operating procedure (SOP)
-
-
NCI PDMR EXCLUSION CRITERIA: Patients with complete response
-
NCI PDMR EXCLUSION CRITERIA: Patients with invasive fungal infections
-
NCI PDMR EXCLUSION CRITERIA: Patients with active and/or uncontrolled infections or who are still recovering from an infection
- Actively febrile patients with uncertain etiology of febrile episode
- All antibiotics for non-prophylactic treatment of infection should be completed at least 1 week (7 days) prior to collection
- No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
-
NCI PDMR EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e. quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HBV/HCV without documented resolution
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Observational (biospecimen collection, chart review)
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo CT, PET/CT and/or MRI throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years. |
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Undergo PET/CT
Inne nazwy:
Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
Inne nazwy:
Medical charts are reviewed and data is collected
Inne nazwy:
Undergo paracentesis |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Procure, store and distribute longitudinal biospecimens and associated clinical data
Ramy czasowe: Up to 10 years
|
Will procure, store and distribute longitudinal biospecimens and associated clinical data for current and future cancer research in order to elucidate molecular mechanisms of sensitivity and intrinsic or acquired resistance to standard of care systemic therapies, including immunotherapy. Cases will be grouped according to patient demographics, cancer type and treatment regimen. Statistical analysis will be descriptive and will be analyzed for each Biospecimen Source Site (BSS) as well as study aggregate. |
Up to 10 years
|
|
Percentage of enrolled patients by cancer type and treatment regimen overall
Ramy czasowe: Until completion of biospecimen collection, up to 3 years
|
Will assess the percentage of enrolled patients by cancer type and treatment regimen overall and those who contribute samples to the Drug Resistance and Sensitivity Network and other approved investigators. Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of minority and underserved study participants accrued
Ramy czasowe: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of minority and underserved study participants accrued
Ramy czasowe: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Pan-cancer gene panel tumor next generation sequencing test
Ramy czasowe: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution
Ramy czasowe: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling is attempted
Ramy czasowe: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling results are generated
Ramy czasowe: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom samples are obtained at each longitudinal timepoint
Ramy czasowe: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
Ramy czasowe: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Lyndsay N Harris, National Cancer Institute (NCI)
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Choroby układu hormonalnego
- Choroby naczyniowe
- Choroby układu krążenia
- Nowotwory narządów płciowych, mężczyzna
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby narządów płciowych, mężczyzna
- Choroby prostaty
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Choroby jelit
- Choroby układu odpornościowego
- Choroby Układu Oddechowego
- Nowotwory według typu histologicznego
- Nowotwory przewodu pokarmowego
- Nowotwory Układu Pokarmowego
- Choroby Układu Pokarmowego
- Choroby przewodu pokarmowego
- Choroby żołądka
- Nowotwory jelit
- Choroby odbytu
- Choroby narządów płciowych, kobiety
- Choroby płuc
- Choroby hematologiczne
- Nowotwory gruczołów dokrewnych
- Nowotwory głowy i szyi
- Nowotwory Układu Oddechowego
- Nowotwory klatki piersiowej
- Choroby okrężnicy
- Choroby przełyku
- Choroby jajników
- Choroby przydatków
- Nowotwory narządów płciowych, kobiety
- Zaburzenia gonad
- Choroby skórne
- Choroby piersi
- Zaburzenia limfoproliferacyjne
- Zaburzenia immunoproliferacyjne
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Białaczka, mieloidalna
- Rak, Bronchogenny
- Nowotwory oskrzeli
- Guzy neuroendokrynne
- Nowotwory, komórki plazmatyczne
- Zaburzenia hemostatyczne
- Paraproteinemie
- Zaburzenia białek krwi
- Zaburzenia krwotoczne
- Białaczka
- Nevi i czerniaki
- Nowotwory skóry
- Choroby jajowodów
- Nowotwory piersi
- Choroby skóry i tkanki łącznej
- Choroby hemowe i limfatyczne
- Nowotwory prostaty
- Nowotwory żołądka
- Nowotwory płuc
- Nowotwory jelita grubego
- Białaczka, szpikowa, ostra
- Nowotwory przełyku
- Nowotwory jajnika
- Rak, płuco niedrobnokomórkowe
- Szpiczak mnogi
- Rak Drobnokomórkowy Płuc
- Czerniak
- Potrójnie ujemne nowotwory piersi
- Nowotwory jajowodu
- Techniki śledcze
- Lecznictwo
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Nakłucia
- Procedury chirurgiczne, operacyjny
- Techniki chemii, analityczne
- Analiza widma
- Drenaż
- Prowadzenie okazów
- Spektroskopia rezonansu magnetycznego
- Paracenteza
Inne numery identyfikacyjne badania
- NCI-2020-00750
- NCI-2020-00750 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- 10323 (Inny identyfikator: CTEP)
- 10323 (Inny identyfikator: Division of Cancer Treatment and Diagnosis)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .